Stryker (NYSE:SYK) Stock Rating Cut to “Hold” at Canaccord Genuity Group

Canaccord Genuity Group cut shares of Stryker (NYSE:SYK) from a buy rating to a hold rating in a research note published on Friday morning, Marketbeat Ratings reports. Canaccord Genuity Group currently has $300.00 price objective on the medical technology company’s stock, down from their previous price objective of $385.00.

Several other research analysts have also recently issued reports on the company. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a report on Thursday. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Sixteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $355.84.

Stryker Stock Down 6.5%

Shares of NYSE:SYK opened at $291.56 on Friday. The firm’s 50 day moving average price is $292.83 and its 200 day moving average price is $324.51. The stock has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.78. Stryker has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.83% and a net margin of 13.78%. The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same quarter last year, the firm earned $3.19 EPS. The company’s revenue was up 7.6% on a year-over-year basis. As a group, equities research analysts predict that Stryker will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In other news, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Hedge funds have recently modified their holdings of the company. State Street Corp boosted its stake in Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after buying an additional 183,400 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after acquiring an additional 45,478 shares during the period. Bank of America Corp DE acquired a new stake in shares of Stryker in the second quarter worth approximately $1,404,284,000. Royal Bank of Canada increased its position in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after purchasing an additional 481,175 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.